Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Oncoinvent ASA's operating assets for the quarter that ended in Dec. 2025 was kr31.50 Mil. Oncoinvent ASA's operating liabilities for the quarter that ended in Dec. 2025 was kr55.08 Mil. Oncoinvent ASA's Total Assets for the quarter that ended in Jun. 2025 was kr86.75 Mil. Therefore, Oncoinvent ASA's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -0.27.
Oncoinvent ASA Scaled Net Operating Assets Related Terms
Oncoinvent ASA Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.27 mean?
Oncoinvent ASA (CHIX:ONCINO) has a Scaled Net Operating Assets of -0.27 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Scaled Net Operating Assets too high?
Oncoinvent ASA's current Scaled Net Operating Assets is -0.27. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Scaled Net Operating Assets compare to VRTX and REGN?
Oncoinvent ASA's Scaled Net Operating Assets of -0.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Scaled Net Operating Assets is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Scaled Net Operating Assets of -0.27. The stock's GF Value™ is kr19,149.99, compared to a current price of kr1,039.91 — trading 94.6% below its estimated fair value. The current Scaled Net Operating Assets is -0.27. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Scaled Net Operating Assets is -0.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.6% below its estimated GF Value™ of kr19,149.99.
Key valuation signals for CHIX:ONCINO:
Scaled Net Operating Assets: -0.27
GF Value™: kr19,149.99 vs. price of kr1,039.91 (94.6% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
